JP2019509345A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509345A5
JP2019509345A5 JP2019500212A JP2019500212A JP2019509345A5 JP 2019509345 A5 JP2019509345 A5 JP 2019509345A5 JP 2019500212 A JP2019500212 A JP 2019500212A JP 2019500212 A JP2019500212 A JP 2019500212A JP 2019509345 A5 JP2019509345 A5 JP 2019509345A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
total weight
sodium phenylbutyrate
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500212A
Other languages
English (en)
Japanese (ja)
Other versions
JP7136763B2 (ja
JP2019509345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/057415 external-priority patent/WO2017160345A1/en
Publication of JP2019509345A publication Critical patent/JP2019509345A/ja
Publication of JP2019509345A5 publication Critical patent/JP2019509345A5/ja
Priority to JP2022076939A priority Critical patent/JP2022106927A/ja
Application granted granted Critical
Publication of JP7136763B2 publication Critical patent/JP7136763B2/ja
Priority to JP2024055290A priority patent/JP2024081748A/ja
Priority to JP2025188821A priority patent/JP2026027401A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500212A 2016-03-15 2016-10-17 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用 Active JP7136763B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022076939A JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2024055290A JP2024081748A (ja) 2016-03-15 2024-03-29 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2025188821A JP2026027401A (ja) 2016-03-15 2025-11-10 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15
US62/308,614 2016-03-15
PCT/US2016/057415 WO2017160345A1 (en) 2016-03-15 2016-10-17 Palatable compositions including sodium phenylbutyrate and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022076939A Division JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2019509345A JP2019509345A (ja) 2019-04-04
JP2019509345A5 true JP2019509345A5 (enExample) 2019-11-28
JP7136763B2 JP7136763B2 (ja) 2022-09-13

Family

ID=59847918

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019500212A Active JP7136763B2 (ja) 2016-03-15 2016-10-17 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2022076939A Withdrawn JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2024055290A Pending JP2024081748A (ja) 2016-03-15 2024-03-29 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2025188821A Pending JP2026027401A (ja) 2016-03-15 2025-11-10 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022076939A Withdrawn JP2022106927A (ja) 2016-03-15 2022-05-09 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2024055290A Pending JP2024081748A (ja) 2016-03-15 2024-03-29 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
JP2025188821A Pending JP2026027401A (ja) 2016-03-15 2025-11-10 フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用

Country Status (22)

Country Link
US (6) US20170266115A1 (enExample)
EP (2) EP4104822A1 (enExample)
JP (4) JP7136763B2 (enExample)
KR (3) KR20250150154A (enExample)
AU (1) AU2016398029B2 (enExample)
BR (1) BR112018068665B1 (enExample)
CY (1) CY1125450T1 (enExample)
DK (1) DK3429559T3 (enExample)
ES (1) ES2922749T3 (enExample)
HR (1) HRP20220856T1 (enExample)
HU (1) HUE059630T2 (enExample)
IL (3) IL322955A (enExample)
LT (1) LT3429559T (enExample)
MX (2) MX391305B (enExample)
PL (1) PL3429559T3 (enExample)
PT (1) PT3429559T (enExample)
RS (1) RS63383B1 (enExample)
SA (1) SA518400020B1 (enExample)
SG (1) SG11201807979SA (enExample)
SI (1) SI3429559T1 (enExample)
SM (1) SMT202200386T1 (enExample)
WO (1) WO2017160345A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391305B (es) 2016-03-15 2025-03-21 Acer Therapeutics Inc Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US20230248657A1 (en) * 2020-07-07 2023-08-10 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
JP2005060310A (ja) * 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0509276A (pt) * 2004-04-12 2007-09-04 Pfizer Prod Inc medicamentos de sabor disfarçado em multiparticulados de ruptura
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
ES2597038T3 (es) 2010-12-06 2017-01-13 Degama Berrier Ltd. Composición y método para mejorar la estabilidad y extender la vida útil de bacterias probióticas y productos alimenticios de las mismas
US8897280B2 (en) * 2011-03-29 2014-11-25 Qualcomm Incorporated System and method for clear channel assessment that supports simultaneous transmission by multiple wireless protocols
US20140178484A1 (en) * 2011-05-16 2014-06-26 Sun Pharma Advanced Research Company Ltd. Multi-particulate pharmaceutical composition
JP2012240917A (ja) * 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
CN103687496A (zh) 2011-06-07 2014-03-26 Spai集团有限公司 用于改善敏感性食品添加剂及其食品产品的稳定性并且延长其货架期的组合物和方法
BR112013033192A2 (pt) 2011-06-22 2017-08-08 Gmp Orphan fenilbutirato na forma retal para o tratamento de uma doença neuronal motora, um distúrbio do ciclo de úreia ou câncer
MX2014001556A (es) * 2011-08-12 2014-03-31 Boehringer Ingelheim Vetmed Composicion farmaceutica de sabor enmascarado.
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) * 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN105560203A (zh) 2013-01-28 2016-05-11 万平 定位速释生物粘附剂及其制备方法和应用
JP6147711B2 (ja) * 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
MX391305B (es) 2016-03-15 2025-03-21 Acer Therapeutics Inc Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.

Similar Documents

Publication Publication Date Title
JP2019509345A5 (enExample)
CN1404389B (zh) 时控脉冲给药系统
EP3154523B1 (en) Formulation for oral administration containing mesalazine
JP6316376B2 (ja) アマンタジン組成物および使用方法
US11903908B2 (en) Methods of administering amantadine
JP5491859B2 (ja) リポ酸のペレット
JP2008280351A5 (enExample)
JP2012153724A5 (enExample)
JP2009537611A5 (ja) リポ酸のペレット
JP2008519070A5 (enExample)
HRP20220856T1 (hr) Pripravci ugodna okusa uključujući natrijev fenilbutirat i njihove uporabe
AU2015254874A1 (en) Extended release liquid compositions of metformin
EP3269363B1 (en) Stabilized formulations of cns compounds
KR20170086063A (ko) 디메틸 푸마르산염을 포함하는 제약학적 비드 제제
CN103239425A (zh) 用于曲美他嗪的延长释放的药物组合物
JP2008501741A6 (ja) 多層制御放出性メチルフェニデートペレット
JP2008501741A (ja) 多層制御放出性メチルフェニデートペレット
CN110035751A (zh) 一种维利帕尼缓控释药物组合物及其用途
JP2008519069A5 (enExample)
RU2007115537A (ru) Новые препараты ингибиторов протонного насоса в виде пеллет с модифицированным высвобождением
BRPI0720958A2 (pt) Omposição de duloxetina
CN101478958A (zh) 包含哌啶烷醇和减充血剂的组合的药物组合物
WO2013158638A1 (en) Stable dosage forms of skeletal muscle relaxants with extended release coating
CN104906077B (zh) 一种具有双相释药特性的非诺贝特酸胆碱盐控释制剂及其制备方法
WO2010037849A1 (en) Duloxetine enteric pellets